

***Pre-stems*:
Suffixes used in the selection of INN
August 2021***

Programme on International Nonproprietary Names (INN)

Health Products Policy and Standards (HPS)

Access to Medicines and Health Products (MHP)

***World Health Organization,
Geneva***

© World Health Organization (2021) -This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any means - electronic, mechanical or other - without the prior written permission of WHO. The views expressed in documents by named authors are solely the responsibility of those authors.

*The prestems given have been flagged because they may be selected as official stems ("The use of stems in the selection of International Nonproprietary Names for Pharmaceutical Substances", 2018, WHO/EMP /RHT/TSN/2018.1). At present, they are made available for information and potential guidance to the applicants.

stem

definition

-suffix

-infix-

In bold: new pre-stems selected during the last Consultation.

In bold and underlined: pre-stems newly promoted as stems.

-adenant	antagonists of adenosine receptors
-algron	α_1 -adrenoreceptor agonists
-alkib	ALK (anaplastic lymphoma kinase) inhibitors
-ampator	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators
-atovir	see <i>vir</i>
-batinib	see <i>tinib</i>
-bactam	β -lactamase inhibitors
-borbactam	β -lactamase inhibitors, boronic acid derivatives
<u>-bep</u>	<u>from engineered or synthetic protein scaffolds, non-immunoglobulin variable domain derived to engineered or synthetic scaffolds proteins with non-immunoglobulin variable derived binding domains</u>
-berel	beta estrogen receptor agonists
-borbactam	see <i>-bactam</i>
<u>-bresib</u>	<u>inhibitors of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) proteins, antineoplastics</u>
-camra	intracellular adhesion molecule (ICAM-1) derivatives
-camtiv	cardiac myosin activators
-capavir	see <i>vir</i>
-casan	caspase inhibitors
-caserin	serotonin receptor agonists (mostly 5-HT ₂)
-cianine	indocyanine fluorescence dye group

-closporin	ciclosporin derivatives
-codar	see <i>dar</i>
-corat	glucocorticoid receptor agonists
-corilant	glucocorticoid receptor antagonists (<i>non-steroidal</i>)
-corvir	see <i>vir</i>
-cridar	see <i>dar</i>
-dacin	antibiotics, DNA gyrase and topoisomerase IV inhibitors
-dar	<i>drugs used in multidrug resistance</i>
-cridar	acridinecarboxamide derivatives
-codar	pipecolinate derivatives
-spodar	ciclosporin D derivatives
-delpar	PPAR delta agonists
-demstat	see <i>stat</i>
-depsin	depsipeptide derivatives
-dil	<i>vasodilators</i>
<u>-sudil</u>	<u>Rho protein kinase inhibitors</u>
-dutide	see -tide
-ectedin	ecteinascidin derivatives
-enatide	see -tide
<u>-estrant</u>	<u>estrogen antagonists, including estrogen receptor down-regulators</u>
-fadine	monoamine transport inhibitors
-farnib	farnesyl transferase inhibitors
-fenicol	antibacterial antibiotics, chloramphenicol analogues
-fibatide	see <i>tide</i>
-folastat	see <i>-stat</i>

<i>-fulven</i>	antineoplastic, acylfulvene derivatives
<i>-ganan</i>	antimicrobial, bactericidal permeability increasing polypeptides
<i>-gapil</i>	neuronal apoptosis inhibitors, GAPDH
<i>-gratinib</i>	<i>see -tinib</i>
<i>-imepodib</i>	inosine monophosphate dehydrogenase inhibitors
<i>-inapant</i>	inhibitors of inhibition-of-apoptosis proteins (IAPs)
<i>-inurad</i>	urate transporter inhibitors
<i>-kalner</i>	openers of calcium-activated (maxi-K) K ⁺ -channels
<i>-leptin(e)</i>	leptin derivatives
<i>-lintide</i>	See <i>-tide</i>
<i>mab</i>	<i>monoclonal antibodies</i>
under targets	
<i>-ami-</i>	serum amyloid protein (SAP)/amyloidosis
<u>-madlin</u>	<u>E3 ubiquitin-protein ligase Mdm2 (Hdm2) inhibitors</u>
<i>-melanotide</i>	<i>see tide</i>
<u>-meran</u>	<u>messenger RNA (mRNA)</u>
<i>-metkib</i>	MET (mesenchymal epithelial transition factor) kinases inhibitors
<u>-metostat</u>	<i>see stat</i>
<i>-moren</i>	non-peptidic growth hormone secretagogues
<i>-nersen</i>	<i>see -rsen</i>
<i>-nesib</i>	kinesin inhibitors
<i>-neurin</i>	neurotrophins
<i>-nexor</i>	nuclear export inhibitors
<i>nil</i>	<i>benzodiazepine receptor antagonists/agonists</i>

<i>-punil</i>	mitochondrial benzodiazepine receptor (MBR)-selective agonists, also partial or inverse (purine derivatives)
<i>-opran</i>	μ -opioid receptors antagonists
<i>-(o)pterin</i>	pteridine derivatives
<i>-osuran</i>	urotensin receptor antagonists
<i>-otilate</i>	hepatoprotectants, di(propan-2-yl) 2-(2 <i>H</i> -1,3-dithiol-2-ylidene)propanedioate and analogues
<i>-parantag</i>	antagonists of heparin and/or low-molecular weight heparins (LMWH)
<i>-paxar</i>	protease activated receptor type 1 (PAR1) antagonists
<i>-perten</i>	glycine transporter inhibitors
<i>-pirdine</i>	serotonin receptor antagonists
<i>-pixant</i>	purinoreceptor (P2X) antagonists
<i>-plasinin</i>	inhibitors of plasminogen activator inhibitors-type 1 (PAI-1)
<i>-plenib</i>	Spleen tyrosine kinase (Syk) inhibitors
<i>-prinin</i>	nootropic agents, purine derivatives
<i>-prodil</i>	<i>N</i>-methyl-D-aspartate (NMDA) receptor antagonists
<i>-protafib</i>	protein tyrosine phosphatase (HPTP) inhibitors
<i>-pultide</i>	see <i>-tide</i>
<i>-punil</i>	see <i>nil</i>

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23668

